top of page
Everads: more effective, durable treatment for retinal diseases.
Our technology facilitates targeted, rapid delivery of therapy via the emerging suprachoroidal delivery route. Leveraging our technology, we are developing treatments to improve efficacy and reduce treatment burden, and also partnering with leading pharmaceutical and biotech companies to enable delivery of novel therapies using our technology.
Everads is an emerging startup with novel delivery technology to treat retinal diseases via suprachoroidal administration and is developing an early-stage pipeline that leverages our technology. Our technology enables delivery of therapy to the choroid and retina via the suprachoroidal space (SCS)….
Everads’ invited to present at the 30th GoForIsrael Investment Conference.
Moshe Weinstein, CEO of Everads, presented the company at the GoForIsrael 2023 conference on May 3rd, 2023 in the innovative technologies in biotech session. This conference, in its 30th year, focuses on connecting between leading global investors and Israel’s most innovative technology companies. Organized by Cukierman & Co. and Catalyst Funds, GoforIsrael has been one of the most influential business conferences in Israel for over 25 years.
bottom of page